BioSpace News Archive

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15th at 4:15 pm Eastern time.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15 at 8:00 a.m. ET.

Resverlogix Corp. announces its participation at the GCFF Virtual Conference 2020 - Investing in Innovation on September 10, 2020.

Facility in Farmingdale, NY, expanding manufacturing and molecular platform to support rapidly growing demand for testing services from universities, nursing homes, physician offices and urgent care facilities.

Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, provided a corporate update, including the announcement of positive and statistically significant top-line results from the Phase 3 LOGICS study.

– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14 th at 3:30 PM EDT –

VYNE Therapeutics Inc. completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.

Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 per cent and significantly slowed kidney function decline1

Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients w